JP2024543139A5 - - Google Patents
Info
- Publication number
- JP2024543139A5 JP2024543139A5 JP2024531129A JP2024531129A JP2024543139A5 JP 2024543139 A5 JP2024543139 A5 JP 2024543139A5 JP 2024531129 A JP2024531129 A JP 2024531129A JP 2024531129 A JP2024531129 A JP 2024531129A JP 2024543139 A5 JP2024543139 A5 JP 2024543139A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- binding protein
- protein according
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282590P | 2021-11-23 | 2021-11-23 | |
| US63/282,590 | 2021-11-23 | ||
| US202263383173P | 2022-11-10 | 2022-11-10 | |
| US63/383,173 | 2022-11-10 | ||
| PCT/US2022/080428 WO2023097275A1 (en) | 2021-11-23 | 2022-11-23 | Anti-ngf antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543139A JP2024543139A (ja) | 2024-11-19 |
| JP2024543139A5 true JP2024543139A5 (cg-RX-API-DMAC7.html) | 2025-12-03 |
Family
ID=86540392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531129A Pending JP2024543139A (ja) | 2021-11-23 | 2022-11-23 | 抗ngf抗体及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20250011410A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4436602A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024543139A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240141160A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022397400A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3238769A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006267A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023097275A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116096741B (zh) | 2020-07-10 | 2024-10-18 | 因外泰克斯公司 | 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法 |
| KR20250137204A (ko) | 2022-12-27 | 2025-09-17 | 인베티엑스 인코포레이티드 | 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 |
| AU2023415535A1 (en) | 2022-12-27 | 2025-07-10 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| WO2025245092A1 (en) * | 2024-05-20 | 2025-11-27 | Invetx, Inc. | Anti-ngf antibodies and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1575517T3 (da) * | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| US8082436B2 (en) | 2008-07-08 | 2011-12-20 | Dell Products L.P. | Enhanced UEFI framework layer |
| SG187592A1 (en) * | 2010-07-23 | 2013-03-28 | Univ Boston | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| ES2665954T3 (es) * | 2010-08-19 | 2018-04-30 | Zoetis Belgium S.A. | Anticuerpos anti-NGF y su uso |
| BR112020017701A2 (pt) * | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | Anticorpos anti-ngf e métodos dos mesmos |
| SG11202104120VA (en) * | 2018-10-31 | 2021-05-28 | Delinia Inc | Multivalent regulatory t cell modulators |
| TW202237648A (zh) * | 2020-11-18 | 2022-10-01 | 美商開拓免疫醫療公司 | 抗marco抗體及其用途 |
-
2022
- 2022-11-23 US US18/712,401 patent/US20250011410A1/en active Pending
- 2022-11-23 AU AU2022397400A patent/AU2022397400A1/en active Pending
- 2022-11-23 KR KR1020247020568A patent/KR20240141160A/ko active Pending
- 2022-11-23 JP JP2024531129A patent/JP2024543139A/ja active Pending
- 2022-11-23 EP EP22899552.8A patent/EP4436602A4/en active Pending
- 2022-11-23 WO PCT/US2022/080428 patent/WO2023097275A1/en not_active Ceased
- 2022-11-23 CA CA3238769A patent/CA3238769A1/en active Pending
- 2022-11-23 MX MX2024006267A patent/MX2024006267A/es unknown
-
2023
- 2023-07-06 US US18/348,173 patent/US12110322B2/en active Active
-
2024
- 2024-01-23 US US18/420,296 patent/US12378308B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250051457A1 (en) | Asgr inhibitors | |
| Wang et al. | Reshaping antibody diversity | |
| Osbourn et al. | Current methods for the generation of human antibodies for the treatment of autoimmune diseases | |
| JP6587609B2 (ja) | 強皮症治療のための抗ccl2及び抗loxl2併用療法 | |
| KR20140005864A (ko) | 미오스타틴에 결합하는 항체, 조성물 및 방법 | |
| EP2761064B1 (en) | Molecular display method | |
| EP2836516B1 (en) | Anti-adamts-5 antibody, derivatives and uses thereof | |
| JP7858629B2 (ja) | Fgfr3抗体および使用の方法 | |
| JP2021518168A (ja) | 拮抗的抗原結合タンパク質 | |
| Qi et al. | Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis | |
| US20200397864A1 (en) | Treating rotator cuff conditions | |
| TW202000232A (zh) | 用以治療或預防異位性骨化之醫藥組成物 | |
| JP7777831B2 (ja) | Dnaポリメラーゼの5’→3’エキソヌクレアーゼ活性ドメインに特異的に結合する抗体 | |
| WO2016043577A1 (en) | Ig-like molecules binding to bmp4 | |
| Xia et al. | Anti-DNA antibody mediated catalysis is isotype dependent | |
| CN113912728A (zh) | 降低抗人白介素-33单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 | |
| Shao et al. | Specific recognition of a single-stranded RNA sequence by a synthetic antibody fragment | |
| US20130130268A1 (en) | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof | |
| RU2528739C2 (ru) | Способ получения пептидов, специфично распознающих определенные типы клеток и предназначенных для терапевтических целей | |
| TW201726726A (zh) | Asgr抑制劑 | |
| EP4442704A1 (en) | Peptide having framework sequence for random region placement and peptide library composed of said peptide | |
| Teplyakov et al. | On the domain pairing in chimeric antibodies | |
| CN117285621A (zh) | 靶向sars-cov-2 s蛋白的抗原结合蛋白及其应用 | |
| WO2023121506A1 (ru) | Средство и способ терапии заболеваний, вызываемых вирусом sars-cov-2 | |
| EP3356388A2 (en) | Compounds binding to the fbg domain of tenascin and uses thereof |